ClinicalTrials.Veeva

Find clinical trials for Glioblastoma (GBM) in Durham, NC

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Glioblastoma
Recurrence
Brain Cancer
Glioma
Astrocytoma
Cancer
Gliosarcoma

Glioblastoma (GBM) trials near Durham, NC, USA:

INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-Diagnosed Glioblastoma (GBM)

efficacy of INO-5401 and INO-9012 in combination with cemiplimab (REGN2810), with radiation and chemotherapy, in subjects with newly-diagnosed glioblastoma...

Active, not recruiting
Glioblastoma
Drug: Temozolomide
Biological: INO-5401

Phase 1, Phase 2

Inovio Pharmaceuticals
Inovio Pharmaceuticals

Chapel Hill, North Carolina, United States and 20 other locations

lerapolturev in the subcutaneous area (under the skin) around the lymph nodes of the head and neck for adult patients diagnosed with recurrent glioblastoma...

Not yet enrolling
Recurrent Supratentorial Glioblastoma
Drug: Lerapolturev
Drug: Lomustine Pill

Phase 2

Darell Bigner

Durham, North Carolina, United States

The primary purpose of the study is to determine the efficacy of an investigational therapy called DCVax(R)-L in patients with newly diagnosed GBM...

Active, not recruiting
Glioblastoma
Glioblastoma Multiforme
Drug: Dendritic cell immunotherapy

Phase 3

Northwest Biotherapeutics
Northwest Biotherapeutics

Chapel Hill, North Carolina, United States and 85 other locations

Locations recently updated

Glioblastoma (GBM) adaptive, global, innovative learning environment (GBM AGILE) is an international, seamless Phase II/II....

Enrolling
Glioblastoma
Biological: ADI-PEG 20
Drug: VT1021

Phase 2, Phase 3

Global Coalition for Adaptive Research

Durham, North Carolina, United States and 60 other locations

The purpose of this study is to evaluate patients with glioblastoma that is MGMT-methylated (the MGMT gene is altered by a chemical change)....

Active, not recruiting
Brain Neoplasms
Other: Nivolumab Placebo
Drug: Nivolumab

Phase 3

Bristol-Myers Squibb (BMS)
Bristol-Myers Squibb (BMS)

Durham, North Carolina, United States and 122 other locations

The purpose of this first-in-human (FIH) study of [177Lu]-NeoB is to characterize the safety, tolerability, pharmacokinetics (PK) as well as the dist...

Enrolling
Neoplasms
Drug: LCZ696
Drug: [177Lu]-NeoB

Phase 1, Phase 2

Advanced Accelerator Applications

Durham, North Carolina, United States and 13 other locations

The purpose of this study is to assess progression-free survival (PFS) and overall survival (OS) in newly diagnosed Glioblastoma (GBM...

Enrolling
Glioblastoma
Drug: SOC: Temozolomide
Combination Product: Placebo

Phase 2

Imvax

Chapel Hill, North Carolina, United States and 22 other locations

are also impermeable to the passage of therapeutic molecules from the blood to the brain. The development of effective treatments against glioblastoma...

Enrolling
Glioblastoma
Recurrent Glioblastoma
Device: SonoCloud-9 (SC9)
Drug: Carboplatin

Phase 3

Carthera

Chapel Hill, North Carolina, United States and 12 other locations

To test the effectiveness and safety of Optune® given concomitantly with radiation therapy (RT) and temozolomide (TMZ) in newly diagnosed GBM...

Active, not recruiting
Glioblastoma Multiforme
Device: Optune®
NovoCure
NovoCure

Chapel Hill, North Carolina, United States and 132 other locations

The purpose of this study is to establish the recommended phase 2 dose of eflornithine in combination with temozolomide in patients whose glioblastoma...

Enrolling
Glioblastoma
Glioblastoma Multiforme
Drug: Temozolomide
Drug: Eflornithine (Dose Level 2)

Phase 1

Orbus Therapeutics

Durham, North Carolina, United States and 7 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems